drugset / Trial / NCT03820141
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
Phase 2
Active not recruiting
51 enrolled
The Methodist Hospital Research Institute
AstraZeneca · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.
Timeline
- Start
- 2020-06-30
- Primary completion
- 2024-10-30
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1120 mg | Intravenous |
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |